P6 - Poster Session VI

Event Time: Friday April 28, 2017 8:30 am to 5:30 pm
Topic(s): Aging, Dementia, Cognitive, and Behavioral Neurology, Cerebrovascular Disease and Interventional Neurology, Epilepsy/Clinical Neurophysiology (EEG), General Neurology, Movement Disorders, MS and CNS Inflammatory Disease, Neuro Trauma, Critical Care, and Sports Neurology, Neuromuscular and Clinical Neurophysiology (EMG), Neuro-oncology, Neuro-ophthalmology/Neuro-otology
Director(s):
Description: A series of thematic abstract presentations in poster format presented Sunday through Friday with evening stand-by times for authors. The specific stand-by time for this session is 4:00 pm to 5:30 pm.
Completion Message:
CME Credits: 0
Core Competencies:

Abstract Presenters

Parkinson's Disease: Phenomenology, Epidemiology and Observational Studies
Start Time Pub. Title Presenter
4:00 PM 001 'Advanced' Parkinson's disease characteristics in clinical practice: results from the OBSERVE-PD study, a cross-sectional observational study of 2615 patients Alfonso Fasano
Disclosure:
Dr. Fasano has nothing to disclose.

4:00 PM 002 Socioeconomic factors are associated with different medication side effect profiles in Parkinson's Disease patients Daniella Sisniega
Disclosure:
Dr. Sisniega has nothing to disclose.

4:00 PM 003 Gait Parameters Across Parkinson’s Disease Patients Treated With Psychotropics Daniel Martinez-Ramirez, MD
Disclosure:
Dr. Martinez-Ramirez has nothing to disclose.

4:00 PM 004 Racial Disparities in Parkinsons Disease at a Tertiary Movement Disorders Center Chantale Branson, MD
Disclosure:
Dr. Branson has nothing to disclose.

4:00 PM 005 Patient's Perspective of Physicians Counseling on Exercise in Parkinson's Disease (PD) Jung Yeon Park, MD
Disclosure:
Dr. Park has nothing to disclose.

4:00 PM 006 Through new eyes: gaze analysis of Parkinson disease patients performing the Symbol Digit Modalities Test Yassar Alamri
Disclosure:
Dr. Alamri has nothing to disclose.

4:00 PM 007 Impact of Off time on Quality of Life and Caregiver Burden in Parkinson’s Disease Phaedra Dowell, MD
Disclosure:
Dr. Dowell has nothing to disclose.

4:00 PM 008 Professional exposure to pesticides and heavy metals hastens Parkinson Disease onset Pierre-Luc Gamache
Disclosure:
Dr. Gamache has nothing to disclose.

4:00 PM 009 Parkinson's disease impact on computer use. A patients' and caregivers' perspective Zoe Katsarou, MD
Disclosure:
Dr. Katsarou has nothing to disclose.

4:00 PM 010 Does Psychological Stress Affect the Progression of Parkinson's Disease Amie Hiller, MD
Disclosure:
Dr. Hiller has nothing to disclose.

4:00 PM 011 Which Parkinson disease patients are most and least active? Lynn Chouhfeh, MD
Disclosure:
Dr. Chouhfeh has nothing to disclose.

4:00 PM 012 Contrast Sensitivity and Executive Dysfunction in Parkinson Disease and Healthy Older Adults Raima Memon
Disclosure:
Dr. Memon has nothing to disclose.

4:00 PM 013 Clinico-neuropathological classification of Parkinson's disease subtypes Daniela Petrova
Disclosure:
Dr. Petrova has nothing to disclose.

4:00 PM 014 Comparison of Clinical Features Among Parkinson Disease Subtypes Takuya Konno
Disclosure:
Dr. Konno has nothing to disclose.

4:00 PM 015 Communication gaps on OFF periods in Parkinson’s disease: A linguistic patient-physician dialogue analysis David Squillacote, MD
Disclosure:
Dr. Squillacote has received personal compensation for activities with Acorda Therapeutics, Inc as an employee.

Movement Disorders: Tics, Tremor & Ataxia II
Start Time Pub. Title Presenter
4:00 PM 016 A Prospective Longitudinal Study of Antipsychotic Safety in Children with Tourette Syndrome Tamara Pringsheim, MD
Disclosure:
Dr. Pringsheim has nothing to disclose.

4:00 PM 017 Next-generation neuroactive steroid SAGE-217 in a single-ascending dose study George Nomikos
Disclosure:
Dr. Nomikos has received personal compensation for activities with Sage Therapeutics, Inc.

4:00 PM 018 Spinocerebellar Ataxias types 3 and 10 - Relation between the onset or worsening of the Ataxia with the gestational period and postpartum. Patricia Bonilha
Disclosure:
Dr. Bonilha has nothing to disclose.

4:00 PM 019 What are the phenotypes of Brazilian patients with autossomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS)?: Neurological, ophthalmological and neuroimaging features of seven genetically confirmed cases. Flavio Rezende Filho
Disclosure:
Dr. Rezende Filho has nothing to disclose.

4:00 PM 020 Apathy in adolescents with Tourette syndrome (TS), more than a teenager attitude Wissam Deeb, MD
Disclosure:
Dr. Deeb has nothing to disclose.

4:00 PM 021 A novel CABC1/ADCK3 mutation in Adult-onset cerebellar ataxia Kalyan Malgireddy
Disclosure:
Dr. Malgireddy has nothing to disclose.

4:00 PM 022 Abnormal Findings in Polisomnographic Records of Patients with Spinocerebellar Ataxia Type 2 (SCA2) Lívia Oliveira
Disclosure:
Dr. Oliveira has nothing to disclose.

4:00 PM 023 Association of Tic Disorders with Poor Academic Performance. A longitudinal, mainstream-population based study Esther Cubo
Disclosure:
Dr. Cubo Delgado has nothing to disclose.

4:00 PM 024 A Novel Deep Brain Stimulation Programming Paradigm for Essential Tremor Jessica Karl, PA
Disclosure:
Dr. Karl has nothing to disclose.

4:00 PM 025 Severity Assessment, Functional Capacity and Balance in Patients with Spinocerebellar Ataxias (SCAs): comparison between types 3 and 10. Paula Marques
Disclosure:
Dr. Marques has nothing to disclose.

4:00 PM 026 Lateralization of fine motor actions in Tourette syndrome persisting through adulthood Davide Martino
Disclosure:
Dr. Martino has nothing to disclose.

4:00 PM 027 An Uptick in Tics: Acute Worsening of Tourette’s Syndrome on Varenicline Shivam Om Mittal, MD
Disclosure:
Dr. Mittal has nothing to disclose.

4:00 PM 028 Treatment of Holmes Tremor by Deep Brain Stimulation of the Prelemniscal Radiations. Thomas Foutz, MD, PhD
Disclosure:
Dr. Foutz has nothing to disclose.

4:00 PM 029 What factors predict Fitbit adherence in Stroke and Parkinson disease? Katrina Schrader
Disclosure:
Dr. Schrader has nothing to disclose.

4:00 PM 030 NA NA NA
Disclosure:

Neuro-opthalmology/Neuro-otology II
Start Time Pub. Title Presenter
4:00 PM 031 pRNFL as a predictor of medium/long term disability in MS patients Christian Cordano
Disclosure:
Dr. Cordano has nothing to disclose.

4:00 PM 032 Retinal thinning is uniquely associated with medial temporal lobe atrophy in neurologically normal older adults Michael Ward, MD, PhD
Disclosure:
Dr. Ward has nothing to disclose.

4:00 PM 033 Use of ganglion cell layer measurements on spectral-domain optical coherence tomography as an adjunct for determining the chronicity of occipital lobe lesions Bryan Pham, MD
Disclosure:
Dr. Pham has nothing to disclose.

4:00 PM 034 Bedside Optical Coherence Tomography for Terson’s Syndrome screening in Acute Subarachnoid Hemorrhage: A pilot study Maryo Kohen
Disclosure:
Dr. Kohen has nothing to disclose.

4:00 PM 035 Opposing Effects of Huntington’s Disease on the Retina: What goes up, must come down Sheridan Reed
Disclosure:
Dr. Reed has nothing to disclose.

4:00 PM 036 Mobile Universal Lexicon Evaluation System (MULES): Pre-Season Baseline Concussion Testing for a New Measure of Rapid Picture Naming Lucy Cobbs
Disclosure:
Dr. Cobbs has nothing to disclose.

4:00 PM 037 Gaze-Position Dependent Opsoclonus in Post-Concussive Syndrome Alexandra J. Lloyd-Smith Sequeira
Disclosure:
Dr. Lloyd-Smith Sequeira has nothing to disclose.

4:00 PM 038 The Validity of an Eye Tracker with Low Temporal Resolution to Assess Eye Movements during a Rapid Number Naming Task: Performance of the EyeTribe versus the EyeLink in Controls Jenelle Raynowska
Disclosure:
Dr. Raynowska has nothing to disclose.

4:00 PM 039 Eye Movement Underpinnings of the Mobile Universal Lexicon Evaluation System (MULES): Computerized Analysis of Rapid Picture Naming Using EyeLink Lisena Hasanaj
Disclosure:
Dr. Hasanaj has nothing to disclose.

4:00 PM 040 Saccade Sequences and Rapid Number Naming in Chronic Concussion Doria Gold, MD
Disclosure:
Dr. Gold has nothing to disclose.

4:00 PM 041 Characterizing Ocular Motor Abnormalities in Patients with Vestibular Migraines and Their Response to Migraine Preventive Therapy Stacy Smith, MD
Disclosure:
Dr. Smith has nothing to disclose.

4:00 PM 042 A Retrospective Case Study Characterizing the Oculomotor Abnormalities in Patient with Immune-mediated Cerebellar Ataxias Diana Londoño
Disclosure:
Dr. Londoño has nothing to disclose.

4:00 PM 043 Gentamicin vestibulotoxicity is uncommon with modern dosing regimens: a prospective study using video head impulse testing Duncan Smyth, MD
Disclosure:
Dr. Smyth has received personal compensation from Boeringher Ingelheim (NZ) Ltd.

4:00 PM 044 Increased uncertainty about the direction of gravity in bilateral vestibulopathy correlates with residual utricular function Alexander Tarnutzer
Disclosure:
Dr. Tarnutzer has nothing to disclose.

4:00 PM 045 Central positional vertigo Duilio De Schutter
Disclosure:
Dr. De Schutter has received personal compensation for activities with Abboth as a speaker.

4:00 PM 046 Maintenance home-based neuromodulation therapy with tDCS after induction treatment with rTMS for mal de debarquement syndrome Yoon-Hee Cha, MD
Disclosure:
Dr. Cha has nothing to disclose.

4:00 PM 048 Theta burst stimulation for mal de debarquement syndrome Yoon-Hee Cha, MD
Disclosure:
Dr. Cha has nothing to disclose.

4:00 PM 049 What’s behind cerebellar dizziness? Katharina Feil
Disclosure:
Dr. Feil has nothing to disclose.

4:00 PM 050 Central positional nystagmus due to cerebellar PICA infarctions Wolfgang Heide, MD, FEAN
Disclosure:
Dr. Heide has received personal compensation for activities with Sanofi Aventis and Edoxab.

4:00 PM 051 Video head impulse test for follow up of cranial nerve 3, 4, or 6 paresis Ali Saber Tehrani, MD
Disclosure:
Grant: Illinois Neurological Institute Video head impulse goggles were loaned to our group for research by Interacoustics. .

Neurocritical Care: Brain Death/Organ Donation
Start Time Pub. Title Presenter
4:00 PM 052 Role Of Sulfonylureas In Perihematomal Edema In Spontaneous Intracerebral Hemorrhage Shailesh Male, MD
Disclosure:
Dr. Male has nothing to disclose.

4:00 PM 053 Brain Death Determination - a dataset analysis in Parana State Between 2013-2015 Marlon Caeira
Disclosure:
Dr. Caeira has nothing to disclose.

4:00 PM 054 From diagnosis of brain death to organ procurement - Analysis of data on Parana - Brazil - 2013 to 2015 Marlon Caeira
Disclosure:
Dr. Caeira has nothing to disclose.

4:00 PM 055 Reliability of Brain flow SPECT scan in excluding Brainstem perfusion: A case of false positive Brain SPECT in a diagnosis of brain Death. Wyssem Ramdani, MD
Disclosure:
Dr. Ramdani has nothing to disclose.

4:00 PM 056 The attitude of healthcare providers toward brain death and organ donation Dareen AlShaer, MD
Disclosure:
Dr. Alshaer has nothing to disclose.

4:00 PM 057 Consent rate for organ donation after Brain Death: a single center experience over 11 years. Mohammed Kananeh, MD
Disclosure:
Dr. Kananeh has nothing to disclose.

4:00 PM 058 Buproprion Overdose Mimicking Brain Death: A Case Report Alan Wang, MD
Disclosure:
Dr. Wang has nothing to disclose.

4:00 PM 059 Single or dual brain death exams: tertiary hospital experience over 11 years. Mohammed Kananeh, MD
Disclosure:
Dr. Kananeh has nothing to disclose.

4:00 PM 060 A Case of Guillain Barre Syndrome Mimicking Brain Death and Review of the Literature Sandhya Ravikumar, MD
Disclosure:
Dr. Ravikumar has nothing to disclose.

Neurocritical Care: Intracranial Pressure
Start Time Pub. Title Presenter
4:00 PM 061 Sagittal sinus stenosis as a cause of increased intracranial pressure Hunan Chaudhry, MD
Disclosure:
Dr. Chaudhry has nothing to disclose.

4:00 PM 062 Monitoring Intracranial pressure (ICP) in Severe Traumatic brain Injury decreases Mortality Himanshu Verma
Disclosure:
Dr. Verma has nothing to disclose.

4:00 PM 063 Sinking Skin Flap Syndrome Presenting with Cranial Neuropathies Vanessa Tiongson
Disclosure:
Dr. Tiongson has nothing to disclose.

4:00 PM 064 Dynamic interaction between EEG and ICP: a pilot study based on wavelet coherence Claudia Perez, MD
Disclosure:
Dr. Perez has nothing to disclose.

4:00 PM 065 Ventricular Catheter Tract Hemorrhage as a Risk Factor for Ventriculostomy Related Infection Juhyun Kim
Disclosure:
Dr. Kim has nothing to disclose.

Neurocritical Care: Epilepsy and Seizures
Start Time Pub. Title Presenter
4:00 PM 066 Predictors of Outcome in patients with Status Epilepticus admitted to Neurointensive Care Unit Advait Mahulikar
Disclosure:
Dr. Mahulikar has nothing to disclose.

4:00 PM 068 Preclinical Pharmacology and Pharmacodynamic Interactions of SAGE-547: Relevance to Super Refractory Status Epilepticus (SRSE). Rebecca Hammond
Disclosure:
Dr. Hammond has received personal compensation for activities with Sage Therapeutics as an employee. Dr. Hammond holds stock and/or stock options in Sage Therapeutics, which sponsored research in which Dr. Hammond was involved as an investigator. Dr. Hammond has received research support from Sage Therapeutics.

4:00 PM 069 Predictors of Non convulsive Status Epilepticus Wazim Mohamed, MD
Disclosure:
Dr. Mohamed has nothing to disclose.

4:00 PM 070 Comparative Efficacy of Antiepileptic Drugs in patients with Status Epilepticus admitted to the Neurocritical Care Unit Shishir Rao, MD
Disclosure:
Dr. Rao has nothing to disclose.

Aging, Dementia, Behavioral and Cognitive Neurology ePoster Session
Start Time Pub. Title Presenter
4:00 PM 071 Finger-to-nose test findings in Alzheimer's disease David Bergeron
Disclosure:
Dr. Bergeron has nothing to disclose.

4:00 PM 072 The "Worried Well": Characteristics of Cognitively Normal Patients Presenting to a Rural and Remote Memory Clinic Ryan Verity
Disclosure:
Dr. Verity has nothing to disclose.

4:00 PM 073 Association between Long-Term Slow-Wave Sleep Enhancement and Cognitive Performance Alice La
Disclosure:

4:00 PM 074 Multimodal structural MRI differentiates in vivo the three clinical variants of primary progressive aphasia Federica Agosta
Disclosure:
Dr. Agosta has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with EXCEMED– Excellence in Medical Education.

4:00 PM 075 Cross-sectional associations between clinical and serological evidence of periodontal disease and cognitive impairment in a multi-ethnic elderly population. James Noble, MD
Disclosure:
Dr. Noble has nothing to disclose.

4:00 PM 077 Tau PET Imaging Predicts Cognition in Atypical Variants of Alzheimer’s Disease Jeffrey Phillips, PhD
Disclosure:
Dr. Phillips has nothing to disclose.

4:00 PM 078 Prediction of chronological age from hierarchical brain volumes using a random forest regression can provide a personalized lifetime metric of aging. Camilo Bermudez
Disclosure:
Dr. Bermudez has nothing to disclose.

4:00 PM 079 Making a murderer: Connectivity of brain lesions causing immoral behavior Ryan Darby, MD
Disclosure:
Dr. Darby has nothing to disclose.

4:00 PM 080 Mixed Transcortical Aphasia in Association with Neurodegenerative Disease Usama Tariq
Disclosure:
Dr. Tariq has nothing to disclose.

Aging and Dementia: Therapeutic Approaches II
Start Time Pub. Title Presenter
4:00 PM 081 Brain Exercises for Synaptic Plasticity (BEST Study): A randomized, placebo-controlled cognitive intervention trial for brain health in older adults Tyler Hammond
Disclosure:
Dr. Hammond has nothing to disclose.

4:00 PM 082 A simulation study of the clinical and economic impact of discontinuation rules for a hypothetical disease modifying therapy (DMT) for patients with Alzheimer’s Disease (AD) Anuraag Kansal
Disclosure:
Dr. Kansal has nothing to disclose.

4:00 PM 083 Long-Term Safety And Tolerability Of Escalating Doses Of Crenezumab In Patients With Mild-To-Moderate Alzheimer’s Disease Veronica Asnaghi
Disclosure:
Dr. Asnaghi has received personal compensation for activities with F. Hoffmann-La Roche Ltd. as an employee.

4:00 PM 084 Achieving the optimal profile for Alzheimer's immunotherapy: Rational generation of antibodies specific for toxic Aβ oligomers Steven Plotkin
Disclosure:
Dr. Plotkin has received personal compensation for activities with PromisNeurosciences as a consultant. Dr. Plotkin holds stock options in PromisNeurosciences, and has received research support from PromisNeurosciences.

4:00 PM 085 A Clinical Precision Medicine Approach Reduces Alzheimer’s, Dementia and Vascular Risk and Improves Cognition: A Prospective Cohort Study Richard Isaacson, MD, BA
Disclosure:
Dr. Isaacson has nothing to disclose.

4:00 PM 086 Gender and age are associated with changes in blood biomarkers and cognition after multi-modal Alzheimer's prevention precision medicine intervention Richard Isaacson, MD, BA
Disclosure:
Dr. Isaacson has nothing to disclose.

4:00 PM 087 A comparative study of binding properties of gantenerumab and aducanumab analog to aggregated amyloid-beta Bernd Bohrmann
Disclosure:
Dr. Bohrmann has received personal compensation for activities with F. Hoffmann-La Roche Ltd as an employee.

4:00 PM 088 A Phase 2 Study of Nelotanserin, a Novel 5HT2A Receptor Inverse Agonist, in Dementia with Lewy Bodies and Parkinson’s Disease Dementia Subjects Experiencing Visual Hallucinations Warren Wen
Disclosure:
Dr. Wen has received personal compensation for activities with Axovant as an employee. Dr. Wen holds stock and/or stock options in Axovant.

4:00 PM 090 Effect of donepezil on transcranial magnetic stimulation parameters in Alzheimer's disease Yun Tae Hwang, MD
Disclosure:
Dr. Hwang has nothing to disclose.

4:00 PM 091 Donepezil modulates perceptual learning in Alzheimer’s disease Chris Hardy
Disclosure:
Dr. Hardy has nothing to disclose.

Cognitive and Motor Studies of Aging
Start Time Pub. Title Presenter
4:00 PM 092 Neural substrates of falls in aging: a compensatory mechanism. Gilles Allali
Disclosure:
Dr. Allali has nothing to disclose.

4:00 PM 093 Increased gait variability while dual tasking predicts cognitive decline in older adults: a prospective longitudinal cohort pilot study olivier Beauchet
Disclosure:
Dr. Beauchet has nothing to disclose.

4:00 PM 094 Mental imagery strategy and body position effects on imagining gait in healthy young and old adults: results from a cross-sectional study Harmehr Sekhon
Disclosure:
Dr. Sekhon has nothing to disclose.

4:00 PM 095 Evolution of objective measures of gait and balance with age Tuhin Virmani, MD, PhD
Disclosure:
Dr. Virmani has nothing to disclose.

4:00 PM 096 Resting-state functional network connectivity differs between healthy aged individuals with and without reports of subjective cognitive change Lauren Zajac
Disclosure:
Dr. Zajac has nothing to disclose.

4:00 PM 097 Serum Uric Acid and Cognitive Function in Middle-Aged and Elderly Men: Within Study Cross-Sectional and Prospective Analysis Comparison Vy Nguyen
Disclosure:
Dr. Nguyen has nothing to disclose.

4:00 PM 098 Measures of hippocampal structure and functional connectivity differentiate healthy aged subjects with and without reports of subjective cognitive change Lauren Zajac
Disclosure:
Dr. Zajac has nothing to disclose.

4:00 PM 099 NA NA NA
Disclosure:

4:00 PM 100 NA NA NA
Disclosure:

Aging and Dementia Poster Discussion Session: Novel Approaches in Neurodegenerative Diseases: Genetics, Biomarkers, and Therapies
Start Time Pub. Title Presenter
4:00 PM 101 Clinicopathological contribution of rare deleterious ABCA7 mutations to early-onset Alzheimer disease Tobi Van den Bossche
Disclosure:
Dr. Van den Bossche has nothing to disclose.

4:00 PM 102 Clinical and genetic characterisation of adult onset leukoencephalopathy David Lynch
Disclosure:
Dr. Lynch has nothing to disclose.

4:00 PM 103 In vivo quantification of regional tau and β-amyloid deposition in progressive posterior cortical dysfunction due to Alzheimer disease Gregory S Day, MD, MSc
Disclosure:
Dr. Day has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with DynaMed (EBSCO Health) and MedEdicus. Dr. Day holds stock and/or stock options in ANI Pharmaceuticals. . Day has received research support from Avid Radiopharmaceuticals.

4:00 PM 104 CSF biomarkers suggest a strong role of glial inflammation in the pathogenesis of frontotemporal dementia Julio Rojas -Martinez, MD, PhD
Disclosure:
Dr. Rojas -Martinez has nothing to disclose.

4:00 PM 105 Predicting development of amyotrophic lateral sclerosis in frontotemporal dementia Tim Van Langenhove, MD
Disclosure:
Dr. Van Langenhove has nothing to disclose.

4:00 PM 106 Cortical Amyloid-beta and Slow Gait in Older Adults without Dementia: Influence of Cognition and APOE Genotype Neelesh Nadkarni, MD, PhD
Disclosure:
Dr. Nadkarni has nothing to disclose.

4:00 PM 107 Cognitive Changes after Working Memory Training in Healthy Older Adults: Evidence From a Multi-Site, Randomized Controlled Trial Sharon Simon
Disclosure:
Dr. Simon has nothing to disclose.

4:00 PM 108 Patient and caregiver assessment of perceived benefits from clinical use of amyloid PET imaging Rafid Mustafa
Disclosure:
Dr. Mustafa has nothing to disclose.

4:00 PM 109 Data-driven cluster analysis of neuropsychological data identifies several cognitive subtypes in early onset cognitive impairment Liana Apostolova, MD, FAAN
Disclosure:
Dr. Apostolova has nothing to disclose.

4:00 PM 110 Tau accumulation in normal and impaired older individuals assessed with serial PET Danielle Cosio
Disclosure:
Dr. Cosio has nothing to disclose.

Neuromuscular and Clinical Neurophysiology (EMG): Peripheral Neuropathy III
Start Time Pub. Title Presenter
4:00 PM 111 Small Fibre Neuropathy: Classification and Search for Autoimmunity Against Peripheral Nerve Components Amanda Chan, MD
Disclosure:
Dr. Chan has nothing to disclose.

4:00 PM 112 Guillain-Barre Syndrome: Tertiary Center Experience in Saudi Arabia Ahmad Abulaban, MD
Disclosure:
Dr. Abulaban has nothing to disclose.

4:00 PM 113 HTLV-1 presenting as a motor neuropathy Nina Kim
Disclosure:
Dr. Kim has nothing to disclose.

4:00 PM 114 Comparison of pre and post procedural pain and anxiety related to electromyography/nerve conduction study (EMG/NCS) in patients provided detailed information vs standard of care Karthika Veerapaneni, MD
Disclosure:
Dr. Veerapaneni has nothing to disclose.

4:00 PM 115 Clinical, Radiological and Electrodiagnostic (EMG/NCS) profile in Acute Flaccid Myelitis(AFM) Rifali Patel, MBBS
Disclosure:
Dr. Patel has nothing to disclose.

4:00 PM 116 A case of posterior interosseous nerve entrapment inside lipoma and compressed by collateral arteries in a patient with radial artery excision for coronary artery bypass grafting Alireza Bozorgi, MD
Disclosure:
Dr. Bozorgi has nothing to disclose.

4:00 PM 117 Anderman-like syndrome presenting with a dHMN Yonglu Huang, MD, PhD
Disclosure:
Dr. Huang has nothing to disclose.

4:00 PM 118 Clinical, electrophysiological and histopathological features of IVIG-responsive pure motor neuropathies: Beyond anti-GM1 antibodies and motor conduction block. Pantelis P. Pavlakis, MD
Disclosure:
Dr. Pavlakis has nothing to disclose.

4:00 PM 119 Poems Syndrome Without “M” – Could it be Possible? A Case Report Paulo Eduardo Mestrinelli Carrilho, MD
Disclosure:
Dr. Mestrinelli Carrilho has nothing to disclose.

4:00 PM 120 Terminal latency index (TLI) and sensory electrophysiology in paraproteinemic chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Anza Memon, MD
Disclosure:
Dr. Memon has nothing to disclose.

4:00 PM 121 Sequential EDX testing identifies differential susceptibility of the median nerve to prolonged wrist extension in normal subjects Anne-Lise Nguyen
Disclosure:
Dr. Nguyen has nothing to disclose.

4:00 PM 122 Isolated Bilateral Radial Nerve Palsies in a Newborn Rocio Vazquez Do Campo, MD
Disclosure:
Dr. Vazquez Do Campo has nothing to disclose.

4:00 PM 123 Pathological Findings of Epineurial Microvasculitis in Neuralgic Amyotrophy Tahseen Mozaffar, MD, FAAN
Disclosure:
Dr. Mozaffar has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with aTyr, Alnylam, Alexion, Amicus, Genzyme, Sarepta, MT-Pharma, and Ultragenyx. Dr. Mozaffar has received research support from Alexion, Amicus, aTyr, Genzyme, Grifols, Idera, Ionis Pharmaceuticals, and Ultragenyx.

4:00 PM 124 Gluteal Compartment Syndrome with Neurologic Impairment: Report of Two Cases and Review of the Literature Gregory Kuhlman, MD
Disclosure:
Dr. Kuhlman has nothing to disclose.

4:00 PM 125 The sensitivity of worldwide normative reference values for intraepidermal nerve fiber density for diagnosis of small fiber neuropathy is lower in Chinese-American patients compared to non-Chinese American patients Peter Jin, MD
Disclosure:
Dr. Jin has nothing to disclose.

4:00 PM 126 Weak above the knees: Lumbar Root Non-Hodgkin Lymphoma invasion Neil Datta, MD
Disclosure:
Dr. Datta has nothing to disclose.

4:00 PM 127 Ficolin 3, a potential biomarker for demyelination in diabetic neuropathy Hongxin Chen
Disclosure:
Dr. Chen has nothing to disclose.

4:00 PM 128 Novel Compound Heterozygous Mutation of SH3TC2 in Patients with Charcot-Marie-Tooth Disease Carla Zingariello, DO
Disclosure:
Dr. Zingariello has nothing to disclose.

4:00 PM 129 A case of Anti Ganglioside antibody negative Bickerstaff’s Brainstem Encephalitis- Miller Fisher overlap syndrome Bharti Manwani, MD
Disclosure:
Dr. Manwani has nothing to disclose.

4:00 PM 130 A Novel Mutation in the SIGMAR1 Gene Underlies Recessive Distal Motor Neuropathy in Oman Nandhagopal Ramachandiran, MBBS, DM, FAAN, FRCP
Disclosure:
Dr. Ramachandiran has nothing to disclose.

4:00 PM 132 Diagnostic Accuracy of Electromyography Referrals, with a Focus on Carpal Tunnel Syndrome Shivkumar Bhadola
Disclosure:
Dr. Bhadola has nothing to disclose.

4:00 PM 133 Failed Back Surgery Syndrome: is there a small fiber involvement? A contact heat evoked potentials (CHEPs) study Luiz Felipe Dantas Pagliarini, MD
Disclosure:
Dr. Dantas Pagliarini has nothing to disclose.

4:00 PM 134 Normal parameters of the blink reflex test among Sudanese population Amani Musa
Disclosure:
Dr. Musa has nothing to disclose.

4:00 PM 135 A Quality Improvement Strategy: Ulnar Nerve Conduction Study of the First Dorsal Interosseous Muscle Charenya Anandan, MD
Disclosure:
Dr. Anandan has nothing to disclose.

4:00 PM 137 Late-onset unilateral peripheral neuropathy in a patient with chromosome 15q11.2 deletion Sumanjit Kaur, MD
Disclosure:
Dr. Kaur has nothing to disclose.

4:00 PM 138 Facial Diplegia and Autoimmune Hepatitis After Pembrolizumab Therapy Micah Yost, DO
Disclosure:
Dr. Yost has nothing to disclose.

4:00 PM 139 Autonomic dysfunction following coronary artery bypass surgery Meenakshi Sundaram Salvadeeswaran
Disclosure:
Dr. Salvadeeswaran has nothing to disclose.

4:00 PM 140 Motor neuronopathy and myelopathy in Leber’s hereditary optic neuropathy Russell Sawyer
Disclosure:
Dr. Sawyer has nothing to disclose.

4:00 PM 141 Evaluation of median nerve T2 signal changes in patients with surgically treated carpal tunnel syndrome Yavuz Samanci
Disclosure:
Dr. Samanci has nothing to disclose.

4:00 PM 142 Increased sNCAM levels in acute peripheral demyelination Adam Niezgoda
Disclosure:
Dr. Niezgoda has nothing to disclose.

4:00 PM 143 NA NA NA
Disclosure:

4:00 PM 144 NA NA NA
Disclosure:

Neuro Trauma and Sports Neurology II
Start Time Pub. Title Presenter
4:00 PM 145 Effects of the New York State Lystedt Law on Concussion-Related Emergency Healthcare Visits among Adolescents, 2005-2014 David Baker
Disclosure:
Dr. Baker has nothing to disclose.

4:00 PM 146 Dual-task gait abnormalities after sport-related concussion and their association with prolonged symptom duration Anna Brilliant
Disclosure:
...I receive royalties from ABC-Clio publishing for the sale of the books, Kids, Sports, and Concussion: A guide for coaches and parents, and Concussions; from Springer International for the book Head and Neck Injuries in Young Athlete; and from Wolters Kluwer for working as an author for UpToDate. ...My research is funded, in part, by a grant from the Football Players Health Study at Harvard which is funded through the NFL Players Association and by philanthropic support from the National Hockey League Alumni Association through the Corey C. Griffin Pro-Am Tournament.

4:00 PM 147 Novel Method of Weighting Cumulative Helmet Impacts Improves Correlation with Brain White Matter Changes After One Football Season of Sub-Concussive Head Blows Kian Merchant-Borna
Disclosure:
Dr. Merchant-Borna has received research support from Brain Scope.

4:00 PM 148 Normative Tandem Gait in Collegiate Student-Athletes: Implications for Clinical Concussion Assessment Jessie Oldham
Disclosure:
Dr. Oldham has nothing to disclose.

4:00 PM 149 Reduced information processing speed and event-related EEG synchronization in traumatic brain injury Sophie Dautricourt
Disclosure:
Dr. Dautricourt has nothing to disclose.

4:00 PM 150 Migraine History and Associated Comorbidities in High School Athletes Magdalena Wojtowicz, PhD
Disclosure:
Dr. Wojtowicz has nothing to disclose.

4:00 PM 151 Utility of Anatomic MRI and Specific Neurological Assessments in mTBI Teena Shetty
Disclosure:
Dr. Teena has received personal compensation for activities with GE-NFL as a medical advisory board member. Dr. Teena has received research support from GE-NFL, Chembio, and Abbott.

4:00 PM 152 Minimum Detectable Change of Tandem Gait Following Concussion Jessie Oldham
Disclosure:
Dr. Oldham has nothing to disclose.

4:00 PM 153 Preseason symptom scores and abnormal exam findings in youth and high school football players. Anthony Savino, MD
Disclosure:
Dr. Savino has received research supported from Riddell and ElMindA.

4:00 PM 154 The Role of Cytosolic PSD-95 Interactor (Cypin) in Traumatic Brain Injury Nicholas Cuccolo
Disclosure:
Dr. Cuccolo has received research support from the American Academy of Neurology scholarship.

4:00 PM 155 Prognosis for consciousness and motor functions recovery in posttraumatic Diffuse Axonal Injury Evgenia Alexandrova, MD
Disclosure:
Dr. Alexandrova has nothing to disclose.

4:00 PM 156 Effects of Exercise on SCAT-3 Performance in Professional Male Athletes Andrew Gardner
Disclosure:
Dr. Gardner has nothing to disclose.

4:00 PM 157 Dual-task gait deficits and acute injury in the year after concussion David Howell
Disclosure:
Dr. Howell has nothing to disclose.

4:00 PM 158 Improved prediction of subconcussive neurophysiological changes by kinematic impulse Katherine Breedlove
Disclosure:
Dr. Breedlove has nothing to disclose.

4:00 PM 159 Rates and significance of new or worse headaches following pediatric mild TBI Dana Coleman
Disclosure:
Dr. Coleman has nothing to disclose.

4:00 PM 160 Traumatic Brain Injury in Domestic Violence Victims: A Retrospective Study at the Barrow Neurological Institute Glynnis Zieman, MD
Disclosure:
Dr. Zieman has nothing to disclose.

4:00 PM 161 A Common Data Language for Clinical Research Studies: The National Institute of Neurological Disorders and Stroke, National Institutes of Health and Department of Defense Traumatic Brain Injury Sports Concussion Common Data Elements Version 1.0 Recommendations Kristen Joseph
Disclosure:
Dr. Joseph has nothing to disclose.

4:00 PM 162 Cervical neurapraxia in college football players with cervical spinal canal narrowing Matthew McCarthy
Disclosure:
Dr. McCarthy has nothing to disclose.

4:00 PM 163 Effect of a Significant Hit to the Head on Depression and Anxiety Neil Nedley
Disclosure:
Dr. Nedley has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Nedley Health Solutions.

4:00 PM 164 The Clinical and Neuropathological Correlates of Second-Impact Syndrome: Case Report of a 17-year-old Female Rugby Player Maryam Mian
Disclosure:
Dr. Mian has nothing to disclose.

4:00 PM 165 Chronic Traumatic Encephalopathy in a 24-year-old former soccer player Joseph Phalen
Disclosure:
Dr. Phalen has nothing to disclose.

4:00 PM 166 Longitudinal MRI and cognitive change in Professional Fighters Charles Bernick, MD
Disclosure:
Dr. Bernick has nothing to disclose.

4:00 PM 167 Barriers to Recovery in Concussion Kristin Halvorsen
Disclosure:
Dr. Halvorsen has nothing to disclose.

4:00 PM 168 Adolescent Sleep-Wake Disturbance Following Concussion Briana Meyer
Disclosure:
Dr. Meyer has nothing to disclose.

4:00 PM 169 Factors Contributing to Subjective Cognitive Symptoms in mTBI Nancy Madigan
Disclosure:
Dr. Madigan has nothing to disclose.

4:00 PM 170 Preseason computerized neurocognitive testing in youth and high school football players Matthew McCarthy, MD
Disclosure:
Dr. McCarthy has nothing to disclose.

Neurologic Complications of Cancer
Start Time Pub. Title Presenter
4:00 PM 171 Retrospective Analysis of Outcomes in Hospitalized Malignant Brain Neoplasm Patients with Status Epilepticus Mina Lobbous, MD
Disclosure:
Dr. Lobbous has nothing to disclose.

4:00 PM 172 Incidence of Peripheral Neuropathy with Docetaxel versus Paclitaxel in Women Treated for Breast Cancer Summer Karafiath, MD
Disclosure:
Dr. Karafiath has nothing to disclose.

4:00 PM 173 Glutamate metabolism in peripheral blood mononuclear cells and neurological complications in lung cancer patients Slawomir Michalak
Disclosure:
Dr Michalak has received fees for speaking from Euroimmun Poland..

4:00 PM 174 The Spectrum of Neurological Adverse Events from Immune Checkpoint Blockade: A Comprehensive Review of Literature Ahmad Daher, MD, PhD
Disclosure:
Dr. Daher has nothing to disclose.

4:00 PM 175 Myasthenic syndrome with pembrolizumab use Upendra Hegde
Disclosure:
Dr. Hegde has nothing to disclose.

4:00 PM 176 Neuromuscular complications occurring in solid tumor cohort treated with PD-1 inhibitors Justin Kao, MBChB
Disclosure:
Dr. Kao has nothing to disclose.

4:00 PM 177 Gamma irradiated microglia produce exosomes that cause molecular and functional changes in neurons: a human model system. Gabriel Arismendi
Disclosure:
Dr. Arismendi has nothing to disclose.

4:00 PM 178 Malignant cerebral edema associated with radiation and laser ablation for brain tumors Stefania Maraka, MD
Disclosure:
Dr. Maraka has nothing to disclose.

4:00 PM 179 Stroke like migraine attacks after radiation therapy (SMART) syndrome a case series of three patients. yasmeen rauf
Disclosure:
Dr. Rauf has nothing to disclose.

4:00 PM 180 Atypical Brain Lesion in Patients with Non-metastatic Cancer: The Critical Role of Histopathology in Diagnosing Cancer-associated Necrotizing CNS Vasculitis Joshua Sheehan
Disclosure:
Dr. Sheehan has nothing to disclose.

4:00 PM 181 Stroke Like Syndrome and Simple Partial Seizures Secondary to Intrathecal Methotrexate Use for the Treatment of Acute Lymphocytic Leukemia Mary-Ann Fares, MD
Disclosure:
Dr. Fares has nothing to disclose.

4:00 PM 182 A Rare Case of AMPA-R Antibody Positive Paraneoplastic Limbic Encephalitis Callie Takahashi
Disclosure:
Dr. Takahashi has nothing to disclose.

4:00 PM 183 Sleep patten in breast cancer patients receiving adjuvant treatment (chemotherapy and/or radiotherapy) Elsayed Tageldin
Disclosure:
Dr. tageldin has nothing to disclose.

4:00 PM 184 Steroid responsive migratory brain lesions causing intractable epilepsy in multiple myeloma. Pilar G. Prieto
Disclosure:
Dr. Prieto Eibl has nothing to disclose.

4:00 PM 185 Seronegative progressive encephalomyelitis with rigidity and myoclonus (PERM) Ehtesham Khalid
Disclosure:
Dr. Khalid has nothing to disclose.

4:00 PM 186 Multifocal neuropathy in vinorelbine treatment for breast cancer Anna Grisold, MD
Disclosure:
Dr. Grisold has nothing to disclose.

4:00 PM 187 A case of neuronal gigantism and cortical thickening: A rare complication of therapeutic radiation Nawal Shaikh, MD
Disclosure:
Dr. Shaikh has nothing to disclose.

4:00 PM 188 Neurologic manifestations of geriatric patients with cancer Bernardo Cacho Diaz, MD
Disclosure:
Dr. Cacho Diaz has nothing to disclose.

4:00 PM 189 Paraneoplastic cerebellar degeneration (PCD) with a normal serum paraneoplastic panel and high anti-Yo titers in the cerebrospinal fluid (CSF): case report and literature review Somayyeh Sabet, MD
Disclosure:
Dr. Sabet has nothing to disclose.

General Neurology: Inflammation, Infections, and Autoimmunity
Start Time Pub. Title Presenter
4:00 PM 190 GRIN1 polymorphisms do not affect susceptibility or phenotype in NMDA receptor encephalitis Gregory Day
Disclosure:
Dr. Day has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with DynaMed (EBSCO Health) and MedEdicus. Dr. Day holds stock and/or stock options in ANI Pharmaceuticals. . Day has received research support from Avid Radiopharmaceuticals.

4:00 PM 191 It’s never lupus…until it is; Primary neuropsychiatric systemic lupus erythematosus presenting as psychosis treated with intravenous immunoglobulin and rituximab; a case study. Emily Watson
Disclosure:
Dr. Watson has nothing to disclose.

4:00 PM 192 Adult onset EBV-associated hemophagocytic lymphohistiocyotosis initially presenting as progressive myelopathy Young Hee Jung
Disclosure:
Dr. Jung has nothing to disclose.

4:00 PM 193 Rabbit Holes of Autoimmunity: Paraneoplastic and Autoimmune Neurological Disorders Ahnas Ahmed
Disclosure:
Dr. Ahmed has nothing to disclose.

4:00 PM 194 A Case Highlighting the Phenotypic Variants Associated with Anti-GQ1B IgG Spectrum Disorders Niraja Suresh, MD
Disclosure:
Dr. Suresh has nothing to disclose.

4:00 PM 195 A case of CJD with concomitant HHV -6 infection Aiga Rakhesh
Disclosure:
Dr. Rakhesh has nothing to disclose.

4:00 PM 196 Seek and you will find: an unusual immune mediated encephalitis with multiple neuronal antibodies. Luke O'Donnell
Disclosure:
Dr. O'Donnell has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Roche.

4:00 PM 197 Fatal Case of Thyrotoxic Periodic Paralysis, Presenting as Hyperacute Ascending Paralysis and Cardiac Arrhythmia Abdul Rahman Alchaki
Disclosure:
Dr. Alchaki has nothing to disclose.

4:00 PM 198 Idiopathic Hypertrophic Cranial Pachymeningitis misdiagnosed as venous sinus thrombosis. Fatemah Alshawaf, MD
Disclosure:
Dr. Alshawaf has nothing to disclose.

4:00 PM 199 Chronic and subacute meningitis: differentiating between neoplastic and non- neoplastic etiologies Mariano Marrodan
Disclosure:
Dr. Marrodan has nothing to disclose.

4:00 PM 200 CNS Lyme Disease Leading to Acute Inflammatory Demyelinating Polyradiculoneuropathy Clarence Li
Disclosure:
Dr. Li has nothing to disclose.

4:00 PM 201 Isoniazid Induced Cerebellar Neurotoxicity in a 45-Year-Old-Woman with Sjogren’s Disease, Chronic Renal Insufficiency, and Extrapulmonary Tuberculosis: A Case Report Hannah Park MD, MD
Disclosure:
Dr. Park, MD has nothing to disclose.

4:00 PM 203 Psuedo-tumoral Form of Wegener's Disease as an Atypical Manifestation of Central Nervous System Involvement Marianela Crespo Arizmendi
Disclosure:
Dr. CRESPO ARIZMENDI has nothing to disclose.

Behavioral and Cognitive Neurology: Emotion/Behavior
Start Time Pub. Title Presenter
4:00 PM 204 Maladaptive Behaviors in Individuals with Angelman Syndrome Anjali Sadhwani
Disclosure:
Dr. Sadhwani has nothing to disclose.

4:00 PM 205 Acute Psychosis as Main Manifestation of Central Pontine Myelinolysis Mangala Gopal
Disclosure:
Dr. Gopal has nothing to disclose.

4:00 PM 206 The Cerebellar Cognitive Affective / Schmahmann Syndrome Scale Franziska Hoche
Disclosure:
Biogen IDEC, Consulting fees. Unrelated to study presented at AAN 2017..

4:00 PM 207 Neuropsychiatric Associations with Gender, Illness Duration and Work Disability Status in a U.S. Based Functional Neurological Disorders Clinic Population Nassim Matin
Disclosure:
Dr. Matin has nothing to disclose.

4:00 PM 208 Catatonia as a rare manifestation of HIV associated psychosis in adolescents. Yoshimi Hisamoto, MD
Disclosure:
Dr. Hisamoto has nothing to disclose.

4:00 PM 209 Title: Evaluation of Possible "Impulsivity" Following Ventromedial Thalamic Nucleus Deactivation in the Rat Using a Fixed Consecutive Number Task Akshay Goswami
Disclosure:
Dr. Goswami has nothing to disclose.

4:00 PM 210 Dextromethorphan/Quinidine Improved Symptoms of Pseudobulbar Affect Irrespective of Concomitant Antidepressant Use Andrea E. Formella, PharmD, BCPP
Disclosure:
Dr. Formella has received personal compensation for activities with Avanir Pharmaceuticals, Inc. as an employee.

4:00 PM 211 Objective biomarkers of Stress in Motor Functional Neurological (Conversion) Disorder Selma Aybek, MD
Disclosure:
Dr. Aybek has nothing to disclose.

4:00 PM 212 Apathy in Parkinson’s disease: mechanisms and associated features Kinan Muhammed
Disclosure:
Dr. Muhammed has nothing to disclose.

4:00 PM 213 A Randomized, Placebo-Controlled, Blinded, Crossover, Single-Center Study of the Effects of Nuedexta in the Treatment of Neurobehavioral Symptoms of Adults with Autism Spectrum Disorder Michael Chez, MD
Disclosure:
Dr. Chez has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Greenwich, UCB, Lundbeck, Eisai, and Sunnovian. Dr. Chez has received research support from EISAI, Greenwich.

4:00 PM 214 Stress-Mediated Alterations of Amygdalar Activation and Cortical Network Coherence Associated with Serotonin Transporter Polymorphisms David Beversdorf, MD, FAAN
Disclosure:
Dr. Beversdorf has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Reviewed clinical cases for Best Doctors. Dr. Beversdorf has received personal compensation in an editorial capacity for Associate Editor for Research in Autism Spectrum Disorders.

4:00 PM 215 Brain Network for Emotional Body Language Reading: Structural and Effective Connectivity Arseny Sokolov
Disclosure:
Dr. Sokolov has nothing to disclose.

Behavioral and Cognitive Neurology: Interventions
Start Time Pub. Title Presenter
4:00 PM 216 Recognizing Cognitive Impairment Is Not Enough: Improved Outcomes with Cognitive Specialty Team Care Norman L. Foster M.D., MD, FAAN
Disclosure:
Dr. Foster has received personal compensation for activities with Piramal and Bristol-Myers Squibb as a consultant. Dr. Foster holds stock and/or stock options in Proactive Memory Services, Inc. Dr. Foster has received research support from GE Healthcare, the Center for Health Improvement, Northern California Institute of Research, and the Veterans Administration.

4:00 PM 217 Improvement in Neurocognitive Function in Moyamoya Patients with Surgical Bypass Alejandro Vargas, MD
Disclosure:
Dr. Vargas has nothing to disclose.

4:00 PM 218 Transcranial direct current stimulation effects in inhibitory control in individuals with attention deficit/hyperactivity disorder Camila Cosmo, MD, PhD
Disclosure:
Dr. Cosmo has nothing to disclose.

4:00 PM 219 Related factors and predictors of cognitive dysfunction in Chronic Kidney Disease Patients on maintenance haemodialysis in Nigeria Lukman Owolabi, PhD, MBBS, MSc, FWAC
Disclosure:
Dr. Owolabi has nothing to disclose.

4:00 PM 220 The Impact of Computer-Based Mindfulness Training on Attention to Novelty in Healthy Older Adults Nicole Feng
Disclosure:
Dr. Feng has nothing to disclose.

4:00 PM 221 NA NA NA
Disclosure:

4:00 PM 222 NA NA NA
Disclosure:

Epilepsy and Clinical Neurophysiology: Clinical Epilepsy V
Start Time Pub. Title Presenter
4:00 PM 223 Prognostication of seizure remission in patients with pharmacoresistant epilepsy: accuracy of physician estimates of seizure freedom after epilepsy surgery Priyanka Sabharwal, MD, MBBS
Disclosure:
Dr. Sabharwal has nothing to disclose.

4:00 PM 224 Visual Hallucinations as a Novel Complication Following Hemispherectomy Monisha Sachdev
Disclosure:
Dr. Sachdev has nothing to disclose.

4:00 PM 225 Understanding Variability in Driving Recommendations for Patients with Seizures Sidrah Mahmud, MD
Disclosure:
Dr. Mahmud has nothing to disclose.

4:00 PM 226 Rhabdomyolysis - an unrecognized adverse effect of Levetiracetam Rodica Bernatowicz
Disclosure:
Dr. Di Lorenzo has nothing to disclose.

4:00 PM 227 Pregnancy outcomes in Women with Epilepsy in Urban Detroit Yuvraj Heir, MD
Disclosure:
Dr. Heir has nothing to disclose.

4:00 PM 228 Characterization of childhood epilepsy in a third level health care center. Erika Paola Guartazaca Guerrero
Disclosure:
Dr. Guartazaca Guerrero has nothing to disclose.

4:00 PM 229 Wada memory performance does not predict memory and seizure outcome after epileptic surgery Sandy Chan
Disclosure:
Dr. Chan has nothing to disclose.

4:00 PM 230 How long does it take from referral to go under the knife? Process Mapping the epilepsy pre-surgical evaluation Adeel Memon
Disclosure:
Dr. Memon has nothing to disclose.

Epilepsy and Clinical Neurophysiology: Therapeutics II
Start Time Pub. Title Presenter
4:00 PM 231 Laser Ablation of Mesial Temporal Structures: A New Treatment for Epilepsy Surgery Andres Kanner, MD
Disclosure:
Dr. Kanner has nothing to disclose.

4:00 PM 233 Brivaracetam enters the brain faster than levetiracetam: a PET study in healthy volunteers Sjoerd J. Finnema
Disclosure:
Dr. Finnema has nothing to disclose.

4:00 PM 234 Hemodynamic properties of SAGE-547 in patients with super-refractory status epilepticus: results from a phase 1/2 clinical trial Helen Colquhoun
Disclosure:
Dr. Colquhoun has received personal compensation for activities with Sage Therapeutics, Inc., as an employee. Dr. Colquhoun holds stock and/or stock options in Sage Therapeutics, Inc.

4:00 PM 235 Tolerability of Midazolam Nasal Spray in Pediatric Subjects with Epilepsy Lindy Bancke, PharmD
Disclosure:
Dr. Bancke has received person compensation for activities with Upsher-Smith Laboratories, Inc. as an employee.

4:00 PM 236 Inhaled Alprazolam, a Potential Rescue Medication, Works Rapidly in Patients with Photosensitive Epilepsy Jacqueline French, MD, FAAN
Disclosure:
Dr. French has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen.

4:00 PM 237 Congenital Malformations in Children of Epileptic Mothers with Intrauterine Exposures to Antiepileptic Drugs and Comparison with a Control Group. Update from Pinar del Rio Epilepsy Pregnancy Multicenter Study, Experience 1996-2016. Juan Miguel Riol Lozano
Disclosure:
Dr. Riol Lozano has nothing to disclose.

4:00 PM 238 Efficacy of adjunctive brivaracetam in patients with secondarily generalized tonic-clonic seizures at baseline: pooled results from long-term follow-up studies Brian Moseley, MD
Disclosure:
Dr. Moseley has received personal compensation for activities with UCB Pharma, Validus Pharmaceuticals, Eisai, and LivaNova. Dr. Moseley has received research support from Nonin Medical Inc.

4:00 PM 239 Online CME Improved Knowledge and Confidence among Neurologists Regarding the Use of Third Generation Antiepileptic Drugs Piyali Chatterjee
Disclosure:
Dr. Chatterjee has nothing to disclose.

4:00 PM 240 Adherence to Classic Ketogenic Diet vs. Modified Atkins Diet in an Observational Cohort Bonnie Wong
Disclosure:
Dr. Wong has nothing to disclose.

4:00 PM 241 Pharmacokinetics of SAGE-547 in patients with super refractory status epilepticus Helen Colquhoun
Disclosure:
Dr. Colquhoun has received personal compensation for activities with Sage Therapeutics, Inc., as an employee. Dr. Colquhoun holds stock and/or stock options in Sage Therapeutics, Inc.

4:00 PM 242 Preliminary Results of Efficacy and Cognitive affects of Cathodal Transcranial Direct Current Stimulation for the Treatment of Epilepsy Wenyi Luo, MD
Disclosure:
Dr. Luo has nothing to disclose.

4:00 PM 243 Evaluation of abuse potential of brivaracetam in healthy recreational CNS depressant users Kerri Schoedel
Disclosure:
Dr. Schoedel has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Altreos Research Partners, Inc.. Dr. Schoedel has received research support from GW Pharmaceuticals, Inc..

4:00 PM 244 Resective epilepsy surgery following Vagal Nerve Stimulator placement Keely Fitzgerald, DO
Disclosure:
Dr. Fitzgerald has nothing to disclose.

4:00 PM 245 Application of the Portable Electromagnetic Navigation System in Epilepsy Surgery Vsevolod Shurkhay
Disclosure:
Dr. Shurkhay has nothing to disclose.

4:00 PM 246 Role of Vagus Nerve Stimulation in the Management of Drug Resistant Refractory Epilepsy in Children with Major Cerebral Malformations Donald Barr
Disclosure:
Dr. Kirmani has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sunovian, Lundbeck.

4:00 PM 247 Plasmapharesis led to clinical recovery in a case of Super Refractory Nonconvulsive Status Epilepticus caused by Hashimoto’s encephalopathy Bharti Manwani, MD
Disclosure:
Dr. Manwani has nothing to disclose.

4:00 PM 248 Retinal Structure and Function During Adjunctive Vigabatrin Treatment: Case Reports of Potentially Significant Changes During a Phase IV Study Kenneth D. Laxer, MD, FAAN
Disclosure:
UCB Pharma:speaking Lundbeck: speaking and scientific advisory board Sunovion: speaking Livanova: speaking UCB: consulting.

4:00 PM 249 An Evaluation of QT/QTc in Adult Patients With Epilepsy Receiving Short-Term IV Carbamazepine Aziz Karim
Disclosure:
Dr. Karim has received personal compensation for activities with Lundbeck LLC and Aptinyx as a consultant.

4:00 PM 250 Pharmacokinetics of IV and Oral Carbamazepine by Renal Function Status William Ravis
Disclosure:
Dr. Ravis has received personal compensation for activities with Fast-Track Drugs & Biologics, LLC. Dr. Ravis has received research support from Fast-Track Drugs & Biologics, LLC and War Eagle Labs.

Non-Atherosclerotic Angiopathies and Cerebral Venous Thrombosis
Start Time Pub. Title Presenter
4:00 PM 251 Adult Moyamoya Syndrome Caused by Varicella Zoster Virus Infection: A Case Series Khalil Husari
Disclosure:
Dr. Husari has nothing to disclose.

4:00 PM 252 Moyamoya and ethnic diversity Khadija Irshad, MD
Disclosure:
Dr. Irshad has nothing to disclose.

4:00 PM 253 Cervicocephalic arterial dissection in a Latin-American cohort: Are there any differences throughout the various stages of life? Maria Pacha
Disclosure:
Dr. Pacha has nothing to disclose.

4:00 PM 254 Comparative analysis between vertebral and carotid dissections from a statewide inpatient dataset. Mohammed Afzal
Disclosure:
Dr. Afzal has nothing to disclose.

4:00 PM 255 Intracranial and Extracranial Neurovascular Manifestations of Takayasu Arteritis Kamila Bond
Disclosure:
Dr. Bond has nothing to disclose.

4:00 PM 256 20 years of Modifying Stroke Risk in Sickle Cell Disease (SCD) Patients: a Single Center Experience of Bone Marrow Transplant (BMT) in SCD. Jessica Carpenter
Disclosure:
Dr. Carpenter has nothing to disclose.

4:00 PM 257 Vertebrobasilar dolichoectasia relates to cerebral microbleeds in a population-based study Fei-Fei Zhai
Disclosure:
Dr. Zhai has nothing to disclose.

4:00 PM 258 Clinical and Neuroimaging Correlations in Cerebral Venous Thrombosis Lakshmi Narasimhan Ranganathan, MD
Disclosure:
Dr. Ranganathan has nothing to disclose.

4:00 PM 259 Efficacy and Safety of Edaravone in Acute Cerebral Venous Thrombosis – A Retrospective Case Control Study in 90 Subjects BOBBY PANIKULAM
Disclosure:
Dr. PANIKULAM has nothing to disclose.

4:00 PM 260 "BEAST" at the University Of Virginia: Demographic and Phenotypic Data of Patients Contributing to a Biorepository to Establish the Etiology Of Sinovenous Thrombosis Nicole Chiota-McCollum, MD
Disclosure:
Dr. Chiota-McCollum has nothing to disclose.

Cerebrovascular Disease Systems of Care and Health Policy
Start Time Pub. Title Presenter
4:00 PM 261 Stroke system of care in Louisiana Digvijaya Navalkele, MD
Disclosure:
Dr. Navalkele has nothing to disclose.

4:00 PM 262 Barriers and facilitators to seeking medical care for young adults with acute stroke - a qualitative study Dylan Jones
Disclosure:
Dr. Jones has nothing to disclose.

4:00 PM 263 Utilization of Hospice Care and Patient Characteristics Associated With Discharge to Hospice in Acute Ischemic Stroke Patients Mai Vuong, MD
Disclosure:
Dr. Vuong has nothing to disclose.

Start Time Pub. Title Presenter
4:00 PM 264 NA NA NA
Disclosure:

Cerebrovascular Disease Systems of Care and Health Policy
Start Time Pub. Title Presenter
4:00 PM 265 Stroke Units with Dedicated Bedside Monitoring Improves Blood Pressure Control Audrey Arango
Disclosure:
Dr. Arango has nothing to disclose.

4:00 PM 266 Transient Ischemic Attack (TIA) Rapid-Access Clinic: Improving outcomes and reducing costs Sarah Hermanson, DNP, ARNP
Disclosure:
Dr. Hermanson has nothing to disclose.

4:00 PM 267 Financial Barriers and Consequences for Canadian Patients with Stroke and Heart Disease Aravind Ganesh, MD
Disclosure:
Dr. Ganesh has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Adkins Research Group. Dr. Ganesh has received compensation for serving on the Board of Directors of SnapDx, AHA Health Ltd.

4:00 PM 268 Efficency in Emergency Stroke Evaluation is Associated with Patient Volume in Louisiana’s Level III Hospitals Sheryl Martin-Schild, MD, PhD
Disclosure:
Dr. Martin-Schild has received personal compensation for activities with Genentech as a speaker.

Cerebrovascular Disease Health Services Research
Start Time Pub. Title Presenter
4:00 PM 269 Getting to the Core of Stroke Care: Real Time Chart Review Improves Hospital Compliance with Core Measures Constance Katsafanas, DO
Disclosure:
Dr. Katsafanas has nothing to disclose.

4:00 PM 270 Hospital Readmissions following Stroke: a Retrospective Study Simy Parikh, MD
Disclosure:
Dr. Parikh has nothing to disclose.

4:00 PM 271 Modified Rankin Scale Disability Status at Day 4 Poststroke is an Informative Predictor of Final Day 90 Outcome Samuel Asanad
Disclosure:
Dr. Asanad has nothing to disclose.

4:00 PM 272 Can we Improve on Neuro-prognostication for Patients with Severe Ischemic Stroke? Julia Bu
Disclosure:
Dr. Bu has nothing to disclose.

4:00 PM 273 The Impact of Post-acute discharge disposition on outcomes in the SWIFT PRIME Trial Samir Belagaje, MD
Disclosure:
Dr. Belagaje has nothing to disclose.

4:00 PM 275 Extended length of stay in cryptogenic stroke patients admitted over weekend Jorge Pesquera, MD
Disclosure:
Dr. Pesquera has nothing to disclose.

4:00 PM 276 Five-year recurrence rate following stroke in the Mashhad Stroke Incidence Study: A population-based study of stroke in the Middle East Amin Amiri
Disclosure:
Dr. Amiri has nothing to disclose.

4:00 PM 277 Association between Demographic Characteristics and Hospital Admission in Patients Presenting to the Emergency Department for Transient Neurological Attack Benjamin Kummer, MD
Disclosure:
Dr. Kummer has nothing to disclose.

4:00 PM 278 Ischemic Stroke Outcomes in Oman: Experience of a University Hospital Based Stroke Registry Arunodaya Gujjar, MBBS, DM, FRCP
Disclosure:
Dr. Gujjar has nothing to disclose.

Prevention of Cerebrovascular Disease
Start Time Pub. Title Presenter
4:00 PM 279 Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis: CREST-2 Update Kevin Barrett, MD
Disclosure:
Dr. Barrett has nothing to disclose.

4:00 PM 280 Selection and Activation of Sites in a Large Multi-center Randomized Clinical Trial Bart Demaerschalk, MD, MSc, FRCPC
Disclosure:
Dr. Demaerschalk has nothing to disclose.

4:00 PM 281 Evaluation of Antithrombotic Bridging Methods in Acute Ischemic Stroke Patients with Atrial Fibrillation Kara Swafford, MD
Disclosure:
Dr. Swafford has nothing to disclose.

4:00 PM 282 Risk Factors Among Young Stroke Victims in Underserved Communities: Are These Strokes Preventable? Matthew Wu
Disclosure:
Dr. Wu has nothing to disclose.

4:00 PM 283 Predicting Pharmacokinetic Versus Pharmacodynamic Aspirin Resistance in Patients Erica Westphal
Disclosure:
Dr. Westphal has nothing to disclose.

4:00 PM 284 The Clinical Implications of Assessing Platelet Responsiveness to Aspirin Using Whole Blood Platelet Aggregation versus Urinary 11-Dehydrothromboxane Testing Erica Westphal
Disclosure:
Dr. Westphal has nothing to disclose.

4:00 PM 285 Difference of Clinical Condition of Ischemic Stroke between Warfarin and Direct Oral Anticoagulants Taizen Nakase
Disclosure:
Dr. Nakase has nothing to disclose.

4:00 PM 286 Assessment of large vessel posterior circulation thrombus with MRI and noncontrast CT. Siddhart Mehta, MD
Disclosure:
Dr. Mehta has nothing to disclose.

4:00 PM 287 Is there a correlation between embolic strokes of undetermined source (ESUS) and patent foramen ovale (PFO)? - A contrasted Transcranial Doppler Ultrasound (cTCD) study. Valéria Scavasine
Disclosure:
Dr. Scavasine has nothing to disclose.

4:00 PM 288 Predictors for Early Atrial Fibrillation Detection Among Cryptogenic Stroke Patients with Insertable Cardiac Monitors: A Single-Center Experience Ganesh Asaithambi, MD
Disclosure:
Dr. Asaithambi has nothing to disclose.

4:00 PM 289 Risk factors of stroke recurrence in a low income country: case of Senegal Daniel Gams Massi, MD
Disclosure:
Dr. Gams Massi has nothing to disclose.

4:00 PM 290 Diabetic microvascular complications and stroke risk in the Asian population in Taiwan: A population based case-control study Wei-Liang Chen
Disclosure:
Dr. Chen has nothing to disclose.

4:00 PM 291 Rates of Adverse Events in the Very Old: A Community Anticoagulation Clinic Study Michael Stanley
Disclosure:
Dr. Stanley has nothing to disclose.

4:00 PM 292 Early cerebral ischemic events in symptomatic carotid stenosis are related to plaque inflammation Chi Hsien Tan
Disclosure:
Dr. Tan has nothing to disclose.

4:00 PM 293 Aspirin use is associated with decreased initial stroke severity in patients with acute ischemic stroke: Pilot study Judd Jensen, MD
Disclosure:
Dr. Jensen has nothing to disclose.

Cardiovascular Issues in Ischemic Stroke
Start Time Pub. Title Presenter
4:00 PM 294 Predictors of atrial fibrillation in patients with cryptogenic stroke Swetha Renati, MD
Disclosure:
Dr. Renati has nothing to disclose.

4:00 PM 295 Acute Stroke Therapy in Infective Endocarditis - Case Series and Systematic Review Robert Marquardt, DO
Disclosure:
Dr. Marquardt has nothing to disclose.

4:00 PM 296 Acute neurologic complications of cardiac catheterization: clinical syndromes and outcomes Sarah Horn, MD
Disclosure:
Dr. Horn has nothing to disclose.

4:00 PM 297 Characterizing Ischemic Stroke and Hemorrhagic Conversion in Infectious Endocarditis Robert Marquardt
Disclosure:
Dr. Marquardt has nothing to disclose.

4:00 PM 298 Altered Cerebral Hemodynamics Causing Neurologic Dysfunction in VA-ECMO Lauren Dunn, MD
Disclosure:
Dr. Dunn has nothing to disclose.

4:00 PM 299 Emergent MRI during a Stroke Alert. Single center experience. Nidhi Kapoor, MD, MBBS
Disclosure:
Dr. Kapoor has nothing to disclose.

4:00 PM 300 Retrospective analysis of Spinal Cord Infarction after Aortic Repair Gino Gialdini
Disclosure:
Dr. Gialdini has nothing to disclose.

4:00 PM 301 Association between stroke subtype and left ventricular dysfunction evolution over time Yi Li, MD
Disclosure:
Dr. Li has nothing to disclose.

Behavioral and Cognitive Neurology: Diagnostic Testing
Start Time Pub. Title Presenter
4:00 PM 302 Cognitive Neurology Toolkit: An iPad App for Mental Status Testing Daniel Press, MD
Disclosure:
Dr. Press has nothing to disclose.

4:00 PM 303 Validation of an ecological test of incidental learning useful at medical office Agostina Galiani
Disclosure:
Dr. Galiani has nothing to disclose.

4:00 PM 304 Argentinian Validation of the Aggie Figures Learning Test (AFLT) Daniel Sanchez
Disclosure:
Dr. Sanchez has nothing to disclose.

4:00 PM 305 Application of Neuropsychological Measures for Patients with Amyotrophic Lateral Sclerosis (ALS) Megan Parmenter
Disclosure:
Dr. Parmenter has nothing to disclose.

4:00 PM 306 Neural basis of the Addenbrooke’s Cognitive Examination III: an 18F-fluorodeoxyglucose positron emission tomography study. Jordi A Matias-Guiu
Disclosure:
Dr. Matias-Guiu has nothing to disclose.

4:00 PM 307 Improving Cognitive Screening Accuracy and Efficiency II: Application for Parkinson’s disease Randall Davis
Disclosure:
Dr. Davis has received personal compensation for activities with Digital Cognition Technologies, Inc. Dr. Davis has received royalty payments from Digital Cognition Technologies, Inc. Dr. Davis holds stock and/or stock options in Digital Cognition Technologies, Inc. Dr. Davis has received research support from Foxconn Corp.

4:00 PM 308 Improving Cognitive Screening Accuracy and Efficiency for Minimally Impaired Individuals Randall Davis
Disclosure:
Dr. Davis has received personal compensation for activities with Digital Cognition Technologies, Inc. Dr. Davis has received royalty payments from Digital Cognition Technologies, Inc. Dr. Davis holds stock and/or stock options in Digital Cognition Technologies, Inc. Dr. Davis has received research support from Foxconn Corp.

4:00 PM 309 Is minimal effort effortless? A qualitative analysis of response bias on memory assessment Rekha Barthelemy
Disclosure:
Dr. Barthelemy has nothing to disclose.

4:00 PM 310 Rapidly progressive dementia as a manifestation of neurosyphilis: case report Kelly Meza
Disclosure:
Dr. Meza Capcha has nothing to disclose.

Behavioral and Cognitive Neurology: Pharmacological Effects
Start Time Pub. Title Presenter
4:00 PM 311 Impact of Psychotropic drugs on Seizure threshold Muhammad Bhatti, MD
Disclosure:
Dr. Bhatti has nothing to disclose.

4:00 PM 312 The Acute and Long Term Toxicity of Dextromethorphan in the Developing Brain Jordan Richardson
Disclosure:
Dr. Richardson has nothing to disclose.

4:00 PM 313 Persistence of Effect of Dextromethorphan Hydrobromide/Quinidine Sulfate (DM/Q) for Pseudobulbar Affect (PBA): Results from a 12-Week Open-Label Extension (OLE) Study Benjamin Rix Brooks, MD
Disclosure:
Dr. Brooks has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Mitsubishi Tanabe Pharma USA. Dr. Brooks has received research support from Medicinova, Neuraltus, Cytokientics,Sathera, Biogen, ITP Pharma, Acceleron, Center for Disease Control.

Behavioral and Cognitive Neurology: Cognitive Deficits in Neurological Disorders
Start Time Pub. Title Presenter
4:00 PM 314 Distinct Behavioural Phenotypes in ALS: A Population Based Factor Analysis Tom Burke
Disclosure:
Dr. Burke has nothing to disclose.

4:00 PM 315 Curious Case of Starvation Induced Wernicke’s Encephalopathy Sharjeel Panjwani, MD
Disclosure:
Dr. Panjwani has nothing to disclose.

4:00 PM 316 Temporal Dot Sign of Transient Global Amnesia - Case series and Literature review Jagkirat Singh, MBBS
Disclosure:
Dr. Singh has nothing to disclose.

4:00 PM 317 Diagnostic Challenges of Fahr’s Disease: A Case Report Ellen Fitzmorris
Disclosure:
Dr. Fitzmorris has nothing to disclose.

4:00 PM 318 Congenital Extra-hepatic porto-systemic shunt presenting with adult-onset fluctuating myelopathy and encephalopathy : a case report Danielle Lux
Disclosure:
Dr. Lux has nothing to disclose.

4:00 PM 319 Retrospective Study of Neurocognitive Outcomes in Autoimmune Encephalitis Julien Hebert, MD
Disclosure:
Dr. Hebert has nothing to disclose.

4:00 PM 320 Longitudinal Assessment of Neuropsychological Performance in Patients with Idiopathic REM Sleep Behavior Disorder Youngsin Jung, MD
Disclosure:
Dr. Jung has nothing to disclose.

4:00 PM 321 Does the cerebellum help solve the "signal-to-noise" problem in sensory processing: evidence from vestibular activation in patients with cerebellar dysfunction Raquel Galvan-Garza
Disclosure:
Dr. Galvan-Garza has nothing to disclose.

4:00 PM 322 Cognitive Fatigue in Multiple Sclerosis: Objective Measures and Structural Correlates Christos Bakirtzis
Disclosure:
Dr. Bakirtzis has nothing to disclose.

4:00 PM 323 Cardiovascular risk factors contribute differentially to cognitive functioning in middle-aged adults Maria-Beatriz Jurado
Disclosure:
Dr. Jurado has nothing to disclose.

4:00 PM 324 Lesion Mapping of Bilateral Motor Threshold in Chronic Post-Stroke Hemiparesis Aaron Boes, MD
Disclosure:
Dr. Boes has nothing to disclose.

4:00 PM 325 Selective Deficits in Prosody after Right Hemisphere Stroke Harry Sutherland-Foggio
Disclosure:
Dr. Sutherland-Foggio has nothing to disclose.

4:00 PM 326 Measurement of Social Cognition in Amyotrophic Lateral Sclerosis: A Population Based Study Tom Burke
Disclosure:
Dr. Burke has nothing to disclose.

4:00 PM 327 What Makes Right Hemisphere Stroke Patients Sound Emotionless? Alexandra Basilakos
Disclosure:
Dr. Basilakos has nothing to disclose.

4:00 PM 328 Combined Mania and Visual-Auditory Hallucinations in a Patient with Isolated Right Thalamic Hemorrhage: the Behavioral Disconnection Syndrome Parunyou Julayanont, MD
Disclosure:
Dr. Julayanont has nothing to disclose.

Disease Modifying Therapy for Multiple Sclerosis: Efficacy and Clinical Trial Outcomes I
Start Time Pub. Title Presenter
4:00 PM 329 Efficacy of Interferon β-1a Subcutaneously Three Times Weekly According to Baseline EDSS/Duration, EDSS, and MSSS Subgroups: Post Hoc Analysis of PRISMS Data Eric Williamson, MD
Disclosure:
Dr. Williamson has received personal compensation for activities with EMD Serono and Teva Pharmaceuticals as an advisory board member.

4:00 PM 330 Safety and efficacy in patients receiving natalizumab therapy in Hungary Tunde Csepany, MD
Disclosure:
Dr. Csepany has nothing to disclose.

4:00 PM 331 The Phase 2b SYNERGY Trial: Analyses of Acute Brain Lesion Recovery Karleyton C. Evans, MD
Disclosure:
Dr. Evans has received personal compensation for activities with Biogen Idec as an employee. Dr. Evans holds stock and/or stock options in Biogen Idec.

4:00 PM 332 Early Fingolimod Treatment Improves Disease Outcomes at 2 and 4 years in Patients with Relapsing-Remitting Multiple Sclerosis Reinhard Hohlfeld, MD
Disclosure:
Dr. Hohlfeld has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Actelion, Biogen, Genzyme-Sanofi, Novartis, Roche. Dr. Hohlfeld has received research support from Biogen, Genzyme-Sanofi, Novartis, Roche.

4:00 PM 333 Safety and Efficacy of Delayed-release Dimethyl Fumarate in Multiple Sclerosis Patients Treated in Routine Medical Practice: Interim Analysis of ESTEEM Nicholas J Everage
Disclosure:
Dr. Everage has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of and holds stock/stock options in Biogen. Dr. Everage holds stock and/or stock options in Employee of and holds stock/stock options in Biogen, which sponsored research in which Dr. Everage was involved as an investigator. Dr. Everage holds stock and/or stock options in Employee of and holds stock/stock options in Biogen.

4:00 PM 334 Evaluating the Effect of Teriflunomide on Cortical Gray Matter Atrophy in the Phase 3 TOPIC Study Robert Zivadinov, MD, PhD, FAAN
Disclosure:
Dr. Zivadinov has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Serono, Genzyme-Sanofi, Claret Medical, Celgene and Novartis. Dr. Zivadinov has received research support from RZ received financial support for research activities from Genzyme-Sanofi, Novartis, Claret Medical, Intekrin-Coherus and Quintiles IMS.

4:00 PM 335 Long term efficacy and safety of Dimethyl Fumarate: A 3 year follow-up in a single MS center Peiqing Qian, MD
Disclosure:
Dr. Qian has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva, Biogen.

4:00 PM 336 Clinical Trial Design protocol Tolervit-MS: TOLerance-induction with dendritic cells treated with VITamin-D3 and loaded with myelin peptides in Multiple Sclerosis patients. Silvia Presas-Rodríguez
Disclosure:
Dr. Presas has nothing to disclose.

4:00 PM 337 Effects of Ocrelizumab on Neurofilament Light Chain and Other Biomarkers of Neuroinflammation and Neurodegeneration in MS: OBOE Study Design Ann Herman
Disclosure:
Dr. Herman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Genentech.

4:00 PM 338 Efficacy of Ocrelizumab on Brain MRI Outcomes in Patients with Early Relapsing Multiple Sclerosis: Pooled Analysis of the OPERA Studies Anthony Traboulsee, MD
Disclosure:
Dr. Traboulsee has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Chugai, F. Hoffmann-La Roche Ltd, Novartis, Sanofi Genzyme and Teva. Dr. Traboulsee has received research support from F. Hoffmann-La Roche Ltd.

4:00 PM 339 Long-term Efficacy of Teriflunomide in Patients Recently Diagnosed With Relapsing Forms of MS Jiwon Oh
Disclosure:
Dr. Oh has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Consulting or speaking fees (Biogen Idec, EMD Serono, Genzyme, Novartis, Roche). Dr. Oh has received research support from Grant/research support (Biogen Idec, Genzyme, MS Society of Canada, Teva).

4:00 PM 340 Treatment with interferon reduces the appearance of lesions in clinically relevant white matter (WM) tracts in patients with clinically isolated syndrome (CIS) Marco Battaglini
Disclosure:
Dr. Battaglini has nothing to disclose.

4:00 PM 341 Benefit of Long-term Treatment With Teriflunomide on Disability Outcomes: Results From TEMSO and TOWER Fred Lublin
Disclosure:
Dr. Lublin has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Consulting and advisory boards: Bayer HealthCare Pharmaceuticals; Biogen Idec; EMD Serono; Novartis; Teva; Actelion; Sanofi/Genzyme; Acorda; F. Hoffmann-La Roche/Genentech; MedImmune; Receptos/Celgene; Forward Pharma; Akros; TG Therapeutics; Abbvie; Rege. Dr. Lublin has received personal compensation in an editorial capacity for Co-Chief Editor of Multiple Sclerosis and Related Disorders. Dr. Lublin has received research support from Research funding from: Biogen Idec; Novartis Pharmaceuticals Corp; Teva Neuroscience, Inc.; Genzyme; Sanofi; Celgene; Transparency Life Sciences; NIH; NMSS.

4:00 PM 342 Assessment of the effect of glatiramer acetate on cerebral gray matter atrophy in multiple sclerosis Subhash Tummala, MD, PhD
Disclosure:
Dr. Tummala has nothing to disclose.

4:00 PM 343 Clinical Efficacy of Interferon β-1a Subcutaneously Three Times Weekly According to Baseline Radiological Characteristics: Post Hoc Analyses of PRISMS Data Flavia Nelson, MD
Disclosure:
Dr. Nelson has nothing to disclose.

4:00 PM 344 The RADIANCE and SUNBEAM phase 3 studies of ozanimod in relapsing multiple sclerosis: study design and baseline characteristics Bruce Cree, MD, PhD, MCR
Disclosure:
Dr. Cree has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbvie, Biogen, EMD Serono, GeNEuro, Novartis, Sanofi Genzyme. Dr. Cree has received research support from Acorda, Hoffman La Roche, MedImmune, Novartis, Receptos and Teva.

4:00 PM 345 5 years effectiveness of fingolimod in daily clinical practice: results of the non-interventional study PANGAEA documenting RRMS patients treated with fingolimod in Germany Tjalf Ziemssen, MD
Disclosure:
Dr. Ziemssen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Almirall, Biogen, Bayer, Merck, Novartis, Roche, Sanofi, Teva for the consulting and speaking services.. Dr. Ziemssen has received research support from Bayer, Biogen, Novartis, Teva, Sanofi Aventis..

4:00 PM 346 Effect of oral fingolimod treatment on brain volume loss in patients with relapsing-remitting multiple sclerosis estimated using Bayesian methodology Guosheng Yin
Disclosure:
Dr. Yin has nothing to disclose.

4:00 PM 347 Short and long-term predictors of relapses or disability worsening in patients with multiple sclerosis in the phase 3 TRANSFORMS study Pavle Repovic, MD, PhD
Disclosure:
Dr. Repovic has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Genzyme, Teva, Genentech, EMD Serono.

4:00 PM 348 Preliminary results of Phase 2 Multicenter Study of Ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of Multiple Sclerosis (RMS) demonstrates rapid and robust B cell depletion Amy Lovett-Racke
Disclosure:
TG Therapeutics - Partial salary support for performing immunological studies for a phase II clinical trial.. Elsevier (Deputy Editor for the Journal of Neuroimmunology). TG Therapeutics - financial support for immunological studies on patients in a phase II clinical trial.

4:00 PM 349 Cladribine tablets in the ORACLE-MS study open-label maintenance period: analysis of efficacy in patients after conversion to clinically definite multiple sclerosis (CDMS) Giancarlo Comi
Disclosure:
Dr. Comi has nothing to disclose.

4:00 PM 350 In treatment-naive patients with relapsing-remitting multiple sclerosis (RRMS), initiating natalizumab earlier is associated with greater disability improvement than delaying treatment: real-world results from the TYSABRI® Observational Program (TOP) Tim Spelman
Disclosure:
Dr. Spelman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Novartis.

4:00 PM 351 Defining High Disease Activity (HDA) in Patients with Relapsing Multiple Sclerosis (RMS) Receiving Placebo in the CLARITY Study Gavin Giovannoni
Disclosure:
Dr. Giovannoni has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbvie, Almirall, Atara Bio, Biogen, Sanofi-Genzyme, Genentech, GSK, Merck, Novartis, Roche, and Teva. Dr. Giovannoni has received personal compensation in an editorial capacity for Elsevier as Editor of MSARDs. Dr. Giovannoni has received research support from Takeda.

4:00 PM 352 Efficacy of Delayed-release Dimethyl Fumarate at Seven-Year Follow-up in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: Integrated Analysis of DEFINE, CONFIRM and ENDORSE Ralf Gold, MD
Disclosure:
Dr. Gold has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceutical Industries Ltd., Biogen Idec, Bayer Schering Pharma, and Novartis. Dr. Gold has received personal compensation in an editorial capacity for Therapeutic Advances in Neurological Diseases, Experimental Neurology and the Journal of Neuroimmunology. Dr. Gold has received research support from Teva Pharmaceutical Industries Ltd., Biogen Idec, Bayer Schering Pharma, Genzyme, Merck Serono, and Novartis.

4:00 PM 353 Durable efficacy of cladribine tablets in patients with multiple sclerosis: analysis of relapse rates and relapse-free patients in the CLARITY and CLARITY Extension studies Per Soelberg-Sorensen
Disclosure:
Dr. Soelberg-Sorensen has received personal compensation for activities with Biogen Idec, Merck Serono, Novartis, Genmab, TEVA, Elan, and GlaxoSmithKline, and Bayer. Dr. Soelberg-Sorensen has received personal compensation in an editorial capacity for European Journal of Neurology, Multiple Sclerosis Journal, European Journal of Neurology, and Therapeutic Advances in Neurological Disorders. Dr. Soelberg-Sorensen has received research support from Biogen Idec, Bayer Schering, Merck Serono, TEVA, Baxter, Sanofi-Aventis, BioMS, Novartis, Bayer, RoFAR, Roche, Genzyme, the Danish Multiple Sclerosis Society, and the Danish Medical Research Council.

4:00 PM 354 Interferon BETA-1B Efficacy in Real-life Clinical Setting: A Long-term Follow-up Study Rocco Totaro
Disclosure:
Dr. Totaro has received personal compensation for activities with Bayer Schering Pharma, Biogen Idec, Merck Serono, Novartis, Sanofi-Aventis, and Teva as a speaker.

4:00 PM 355 Highly active relapsing remitting multiple sclerosis following hematopoietic stem cell transplantation: a case report Amanda Piquet, MD
Disclosure:
Dr. Piquet has nothing to disclose.

4:00 PM 356 Real-life long-term effectiveness of fingolimod in a Swiss relapsing-remitting multiple sclerosis cohort Chiara Zecca, MD
Disclosure:
Dr. Chiara has received research support from Teva Neuroscience, Merck Serono, Biogen Idec, Bayer Schering, Genzyme, and Novartis.

4:00 PM 357 Predictors of Disability in Relapsing-Remitting Multiple Sclerosis (RRMS) During the Glatiramer Acetate Low-frequency Administration (GALA) Study Jessica Alexander
Disclosure:
Dr. Alexander has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Teva.

4:00 PM 358 Effect of early versus delayed treatment (DT) with subcutaneous IFN β-1a (scIFNβ-1a) on radiological activity free (RAF) or clinical activity free (CAF) status in patients with clinically isolated syndrome (CIS): A post-hoc analysis of REFLEXION Mark Freedman, MD, FAAN
Disclosure:
Dr. Freedman has received personal compensation for activities with Bayer HealthCare, Biogen Idec, EMD Canada, Novartis, Sanofi, Teva Canada Innovation, Chugai, Merck Serono, Novartis, Opexa for honoraria, consulting or participating on a advisory board. Dr. Freedman has received research support from Bayer HealthCare and Genzyme.

4:00 PM 359 Multi-center, randomized, double-blinded assessment of teriflunomide in extending the time to a first clinical event in radiologically isolated syndrome (RIS) The TERIS study Christine Lebrun Frenay
Disclosure:
Dr. Lebrun Frenay has nothing to disclose.

4:00 PM 360 Efficacy of Cladribine Tablets 3.5 mg/kg in High Disease Activity (HDA) Subgroups of Patients with Relapsing Multiple Sclerosis (RMS) in the CLARITY Study Gavin Giovannoni, MD
Disclosure:
Dr. Giovannoni has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbvie, Almirall, Atara Bio, Biogen, Sanofi-Genzyme, Genentech, GSK, Merck, Novartis, Roche, and Teva. Dr. Giovannoni has received personal compensation in an editorial capacity for Elsevier as Editor of MSARDs. Dr. Giovannoni has received research support from Takeda.

4:00 PM 361 Impact of Long-term Teriflunomide Treatment on Severe Relapses: Analysis of TEMSO and TOWER Extensions Mathias Mäurer
Disclosure:
Dr. Maurer has received personal compensation for activities with Bayer HealthCare, Biogen, Boehringer Ingelheim, Sanofi Genzyme, EMD Serono, Novartis, Sanofi Genzyme, Talecris, and Teva CNS.

4:00 PM 362 Teriflunomide Is Effective in Reducing Brain Volume Loss in Previously Treated Patients: A Subgroup Analysis of TEMSO SIENA Data Mark S Freedman
Disclosure:
Dr. Freedman has received personal compensation for activities with Bayer HealthCare, Biogen Idec, EMD Canada, Novartis, Sanofi, Teva Canada Innovation, Chugai, Merck Serono, Novartis, Opexa for honoraria, consulting or participating on a advisory board. Dr. Freedman has received research support from Bayer HealthCare and Genzyme.

4:00 PM 363 Effectiveness of Delayed-release Dimethyl Fumarate on Clinical Measures and Patient-reported Outcomes in Newly Diagnosed and Other Early Relapsing-Remitting Multiple Sclerosis Patients: Subgroup Analysis of PROTEC Thomas Berger, MD
Disclosure:
Dr. Berger has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Participated in meetings sponsored by and received honoraria (lectures, advisory boards, consultations) from Almirall, Biogen, Celgene, Genzyme, Merck, Novartis, Octapharma, Roche, Sanofi Adventist/TEVA.. Dr. Berger has received research support from His institution has received financial support by unrestricted research grants (Biogen, Novartis, Roche, Sanofi Aventis/TEVA) and for participation in clinical trials in multiple sclerosis sponsored by Alexion, Bayer, Biogen, Merck, Novartis, Octapharma,.

4:00 PM 364 Prolonged-Release Fampridine Induces Sustained Clinically Meaningful Improvements in Walking Ability in People with Multiple Sclerosis: Results from the ENHANCE Trial Jeremy Hobart, MD
Disclosure:
Dr. Hobart has received personal compensation for activities with Biogen and Genzyme for consulting. Dr. Hobart has received research support from Acorda, Biogen, Genzyme, Global Blood Therapeutics, Merck Serono, Novartis, Tigercat, Vanita.

4:00 PM 365 Effectiveness of fingolimod in patients with relapsing-remitting multiple sclerosis in daily clinical practice in Spain: results from the multivariate pooled analysis Fingoview. Jose Meca-Lallana, MD
Disclosure:
Dr. Meca Lallana has nothing to disclose.

Comparative Efficacy of Disease Modifying Therapies for Multiple Sclerosis
Start Time Pub. Title Presenter
4:00 PM 366 Comparison of Adherence and Persistence to Glatiramer Acetate 40 mg/mL Three-Times Weekly Subcutaneous Injections Versus Oral Therapies in Multiple Sclerosis Helen Trenz
Disclosure:
Dr. Trenz has received personal compensation for activities with Optum as an employee.

4:00 PM 367 SC peginterferon beta-1a every 2 weeks demonstrated better clinical outcomes than SC interferon beta-1a TIW in patients with RMS, using a matching-adjusted comparison of 5 Phase 3 trials Patricia Coyle, MD, FAAN
Disclosure:
Dr. Coyle has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Consulting fees (AbbVie, Accordant, Acorda, Bayer, Biogen Idec, Celgene, Genentech/Roche, Genzyme/Sanofi, Novartis, Serono, Teva).. Dr. Coyle has received research support from Research support (Actelion, Alkermes, Genentech/Roche, MedDay, NINDS, Novartis, Opexa)..

4:00 PM 368 Peginterferon Beta-1a Demonstrated Better Clinical Outcomes than Teriflunomide in Patients with Relapsing MS, Using a Matching-adjusted Comparison of Phase 3 Trials Scott Newsome, DO
Disclosure:
Dr. Newsome has nothing to disclose.

4:00 PM 369 Comparison of treatment retention and efficacy outcomes with fingolimod, interferons and glatiramer acetate in PREFERMS Florian Thomas, MD, MA, PhD, FAAN
Disclosure:
Dr. Thomas has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva, Acorda, Sanofi. Dr. Thomas has received personal compensation in an editorial capacity for Journal of Spinal Cord Medicine.

4:00 PM 370 A Bayesian Random Effects Mixed Treatment Comparison of Daclizumab Versus Other Disease Modifying Treatments for Relapsing-Remitting Multiple Sclerosis Craig Wakeford
Disclosure:
Dr. Wakeford has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with employee of Biogen. Dr. Wakeford holds stock and/or stock options in hold stock/stock options in Biogen.

4:00 PM 371 Advanced Myelin-related MRI Measures in Relapsing Multiple Sclerosis Patients treated with Ocrelizumab or Interferon Beta-1a Over 96 Weeks Shannon Kolind, PhD
Disclosure:
Dr. Kolind has received personal compensation for activities Genzyme, Vertex Pharmaceuticals and Rocheas a speaker and/or consultant.

4:00 PM 372 Comparative analysis of MS outcomes in dimethyl fumarate-treated patients relative to propensity matched fingolimod, interferon, glatiramer acetate, or teriflunomide Timothy Spelman
Disclosure:
Dr. Spelman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Novartis.

4:00 PM 373 Comparable efficacy of fingolimod and natalizumab in real life study Roberta Lanzillo
Disclosure:
Dr. Lanzillo has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck, Novartis, Biogen, Genzyme, Teva and Almirall..

4:00 PM 374 A Matching-adjusted Indirect Comparison of Clinical Effectiveness of Subcutaneous Peginterferon Beta-1a and Intramuscular Interferon Beta-1a for the Treatment of Relapsing Multiple Sclerosis Thomas Scott
Disclosure:
Dr. Scott has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Genentech, Genzyme, Novartis, Teva Neuroscience. Dr. Scott has received research support from Biogen, Genentech, Genzyme, Novartis, Teva Neuroscience.

4:00 PM 375 Comparative Effectiveness of Delayed-release Dimethyl Fumarate Versus Fingolimod and Teriflunomide on Risk of Relapse Jacqueline Nicholas, MD
Disclosure:
Dr. Nicholas has nothing to disclose.

4:00 PM 376 Fingolimod significantly lowers neurofilament light chain blood levels in RRMS patients as compared to interferon beta-1a or placebo Jens Kuhle, MD
Disclosure:
Dr. Kuhle has received research support from Dr Kuhle’s institution (University Hospital Basel) received and used exclusively for research support: consulting fees from Biogen, Novartis, Protagen AG, Roche, Teva; speaker fees from the Swiss MS Society, Biogen, Novartis, Roche, Genzyme; travel expens.

4:00 PM 377 Efficacy of Natalizumab and Fingolimod in Relapsing Remitting Multiple Sclerosis in Real World Clinical Setting: a 2-year follow-up Rocco Totaro
Disclosure:
Dr. Totaro has received personal compensation for activities with Bayer Schering Pharma, Biogen Idec, Merck Serono, Novartis, Sanofi-Aventis, and Teva as a speaker.

4:00 PM 378 Myelin repair and improved axonal integrity over time in relapsing remitting multiple sclerosis; comparative analysis of Fingolimod, Natalizumab and Glatitamer acetate Sara Razmjou
Disclosure:
Dr. Razmjou has nothing to disclose.

4:00 PM 379 Effect of dimethyl fumarate and glatiramer acetate on the immunological profiles and gut microbiota in Multiple Sclerosis patients Ilana Katz Sand, MD
Disclosure:
Dr. Katz Sand has nothing to disclose.

4:00 PM 380 Comparison of 12 month changes in Brain Volume in Long Term Users of Glatiramer Acetate versus Fingolimod in Multiple Sclerosis: Preliminary analysis of a Two-Year Longitudinal Observational Study Justin Honce
Disclosure:
Dr. Honce has received personal compensation for activities with Genentech Inc. as a speaker. Dr. Honce has received research support from Biogen Idec and Novartis Pharmaceuticals for ongoing investigator initiated trials.

4:00 PM 381 Dimethyl fumarate versus interferon for treatment of relapsing-remitting multiple Sclerosis Neda Sattarnezhad, MD
Disclosure:
Dr. Sattarnezhad has nothing to disclose.

4:00 PM 382 PREFERMS study: post hoc analyses of patient retention, key clinical outcomes and patient satisfaction in an African-American patient subgroup Mark Cascione, MD
Disclosure:
Dr. Cascione has received research support from Novartis, Genentech, Biogen, and Genzyme.

4:00 PM 384 Number Needed to Treat Analyses to Assess Clinical Outcomes in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Alemtuzumab or Ocrelizumab Giancarlo Comi
Disclosure:
Dr. Comi has nothing to disclose.

Neuromyelitis Optica Spectrum Disorder, Transverse Myelitis, and Optic Neuritis B
Start Time Pub. Title Presenter
4:00 PM 385 Earlier Treatment of Acute Relapses in Neuromyelitis Optica Spectrum Disorder Leads to Better Outcomes Jessica Coleman
Disclosure:
Dr. Coleman has nothing to disclose.

4:00 PM 386 Defining Area Postrema (AP) Attacks in Autoimmune AQP4 Channelopathies/Neuromyelitis Optica Spectrum Disorders (NMOSD) Eslam Shosha, MD
Disclosure:
Dr. Shosha has nothing to disclose.

4:00 PM 387 Area postrema syndrome more specific than extension of lesion on MRI for Neuromyelitis Optica Spectrum Disorder Divyanshu Dubey, MD
Disclosure:
Dr. Dubey has nothing to disclose.

4:00 PM 388 Oral lipoic acid as a treatment for acute optic neuritis: A blinded, placebo-controlled randomized trial Vijayshree Yadav
Disclosure:
Dr. Yadav has nothing to disclose.

4:00 PM 389 Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: results from a bicentric study Mikael Cohen
Disclosure:
Dr. Cohen has nothing to disclose.

4:00 PM 390 Low Prevalence of anti aquaporin 4 antibody in neuromyelitis optica spectrum disorder and multiple sclerosis in Western Australia Marzena J Fabis-Pedrini, PhD
Disclosure:
Dr. Pedrini has nothing to disclose.

4:00 PM 391 Atypical myelitis of multiple sclerosis: description of a French cohort Carole Lambert
Disclosure:
Dr. Lambert has nothing to disclose.

4:00 PM 392 Color vision impairment following optic neuritis and its association with retinal atrophy Netta Levin, MD, PhD
Disclosure:
Dr. Levin has nothing to disclose.

4:00 PM 393 Detection of Anti Mog Antibodies in Demyelinating Disorders of the Central Nervous System (CNS) Antonio Bertolotto, MD
Disclosure:
Dr. Bertolotto has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Almirall, Biogen, Roche, Merck Serono, Novartis, Teva, Sanofi Genzyme, Mylan.

4:00 PM 394 Lipid profile in neuromyelitis optica spectrum disorder between clinical attack and remission state. Misong Choi
Disclosure:
Dr. Choi has nothing to disclose.

4:00 PM 395 Diffusion Weighted Imaging in a Case of Longitudinally Extensive Transverse Myelitis in Neuromyelitis Optica Lauren Gluck, MD
Disclosure:
Dr. Gluck has nothing to disclose.

Optical Coherence Tomography in Multiple Sclerosis
Start Time Pub. Title Presenter
4:00 PM 396 Retinal Layer Thinning May Reflect Gray Matter Atrophy in Relapsing Remitting Multiple Sclerosis: The Ethnicity Role Samuel Lichtman-Mikol
Disclosure:
Dr. Lichtman-Mikol has nothing to disclose.

4:00 PM 397 Similar retinal pathology in benign & relapsing remitting multiple sclerosis; more evidence that benign multiple sclerosis is not benign. Sara Razmjou
Disclosure:
Dr. Razmjou has nothing to disclose.

4:00 PM 398 Visual pathway damage in different subtipes of multiple sclerosis: an OCT, ffVEP and mfVEP study. Marco Pisa
Disclosure:
Dr. Pisa has nothing to disclose.

4:00 PM 399 Retinal axonal loss in relapsing multiple sclerosis is associated with visual and global disability and MRI and neurphysiological measures of CNS damage Marco pisa
Disclosure:
Dr. pisa has nothing to disclose.

4:00 PM 400 Retinal vascular network in multiple sclerosis patients and healthy controls through angio-OCT and correlations to disease features. Roberta Lanzillo
Disclosure:
Dr. Lanzillo has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck, Novartis, Biogen, Genzyme, Teva and Almirall..

4:00 PM 401 Changes in Retinal Vessel Architecture and Blood Flow in Multiple Sclerosis Richard Nicholas, FRCP
Disclosure:
Dr. Nicholas has nothing to disclose.

4:00 PM 402 Optical Coherence Tomography Segmentation Analysis in Relapsing Remitting versus Progressive Multiple Sclerosis Raed Behbehani
Disclosure:
Dr. Behbehani has nothing to disclose.

4:00 PM 403 Clinical and optical coherence tomography outcome in secondary progressive multiple sclerosis patients after autologous mesenchymal stem cells intrathecal transplantation. Mariola Swiderek-Mariola
Disclosure:
Dr. Swiderek-Mariola has nothing to disclose.

4:00 PM 404 A Preliminary Investigation into the Relationship between Visual Evoked Potential Latency (VEP-L) and Outcome Parameters from Optical Coherence Tomography (OCT) in Patients With Multiple Sclerosis (PwMS) Kojo Tabiri
Disclosure:
Dr. Tabiri has nothing to disclose.

4:00 PM 405 A composite MRI and OCT based measure to explore the visual pathways in primary-progressive Multiple Sclerosis Valentina Poretto
Disclosure:
Dr. Poretto has nothing to disclose.

4:00 PM 406 Self-Reported Cognitive Function and Optical Coherence Tomography (OCT) Measures in Persons with Multiple Sclerosis (MS) Krupa Pandey, MD
Disclosure:
Dr. Pandey has received personal compensation for activities with Biogen, Genzyme, Genentech and Teva as a consultant. Dr. Pandey has received compensation for serving on speaker bureaus for Biogen, Acorda, Genzyme and Teva.

Register Now

Related Courses